


**DESCRIPTION**

<i>Description</i>	Recombinant Human Leucine-Rich Repeat-Containing protein 15 (LRRC15)
<i>Sequence</i>	Native NCBI Accession Number: NM_130830.5 Met1-Gly538 (Extra Cellular Domain)
<i>Expression system</i>	CHO cells
<i>Tag</i>	Human IgG1 Fc (Pro100-Lys330)
<i>Purification</i>	Affinity chromatography
<i>Extinction coefficient</i>	84185 M <sup>-1</sup> .cm <sup>-1</sup> Abs 0.1% (=1 g/l) 0.9 assuming all pairs of Cys residues form cystines
<i>Predicted Molecular Weight</i>	84.8 kDa

**SPECIFICATIONS**

<i>SDS Page</i>	Approx.95 kDa (reducing conditions)
<i>Concentration</i>	1 mg/ml
<i>Purity</i>	>95% by SDS PAGE gel
<i>Formulation</i>	Liquid PBS
<i>Activity</i>	Recognized by the B-G53 anti-LRCC15 in ELISA
<i>Stability and Storage</i>	Store at minimum -20°C. Avoid repeated freeze-thaw cycles

**DATA**



## Leucine-rich repeat-containing protein 15

LRRC15 or Leucine-rich repeat-containing protein 15 is a 581 amino acid type I membrane protein with an extracellular domain of 517 aa (pro-peptide de 21aa) and with no obvious intracellular signaling domains. It has recently been reported as a marker of cancer-associated fibroblasts [1]. This protein has been found to be highly expressed on CAFs within the tumor stroma of many tumor types [2], as well as directly on cancer cells in tumors of mesenchymal origin such as sarcomas. The expression of LRRC15 is upregulated by the pro-inflammatory cytokine TGF $\beta$ .

ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC) designed to target LRRC15, and which has shown significant anti-tumor activity in several tumor models [1, 3].

Overexpression of LRRC15 is positively correlated with grade and independently associated with adverse outcome [4]

## BIBLIOGRAPHY

1. Purcell J.W et al. (2018). LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates. *Cancer Res.* 78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. PMID: 29764866.
2. Dominguez C et al. (2020). Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. *Cancer Discov.* 10(2):232-253. doi: 10.1158/2159-8290.CD-19-0644. PMID: 31699795.
3. Demetri G.D et al. (2019). First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors. *J. Clin. Oncol.* doi: 10.1200/JCO.2019.37.15\_suppl.3004.
4. Ben-Ami E et al. (2020). LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. *Cancers (Basel)*. 12(3):757. doi:10.3390/cancers12030757.
- 5.

International Journal of  
*Molecular Sciences*

an Open Access Journal by MDPI

**Development of Anti-LRRC15 Small Fragments for Imaging Purposes  
Using a Phage-Display ScFv Approach**

Pierre-Emmanuel Baurand; Jérémy Balland; Chloé Reynas; Mélanie Ramseyer; Delphine Vivier;  
Pierre-Simon Bellaye; Bertrand Collin; Catherine Paul; Franck Denat; Kamal Asgarov; Jean-René  
Pallandre; Laurence Ringenbach

*Int. J. Mol. Sci.* 2022, Volume 23, Issue 20, 12677

Products Manufactured and Distributed by:

Diacclone SAS – Part of Medix Biochemica Group

6 Rue Dr Jean-François-Xavier Girod

BP 1985, 25020 Besançon Cedex

France

Tel +33 (0)3 81 41 38 38

Email: [info@diacclone.com](mailto:info@diacclone.com) [www.diacclone.com](http://www.diacclone.com)